Theratechnologies Net Worth

Theratechnologies Net Worth Breakdown

  THTX
The net worth of Theratechnologies is the difference between its total assets and liabilities. Theratechnologies' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Theratechnologies' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Theratechnologies' net worth can be used as a measure of its financial health and stability which can help investors to decide if Theratechnologies is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Theratechnologies stock.

Theratechnologies Net Worth Analysis

Theratechnologies' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Theratechnologies' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Theratechnologies' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Theratechnologies' net worth analysis. One common approach is to calculate Theratechnologies' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Theratechnologies' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Theratechnologies' net worth. This approach calculates the present value of Theratechnologies' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Theratechnologies' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Theratechnologies' net worth. This involves comparing Theratechnologies' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Theratechnologies' net worth relative to its peers.

Enterprise Value

85.14 Million

To determine if Theratechnologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Theratechnologies' net worth research are outlined below:
Theratechnologies had very high historical volatility over the last 90 days
Theratechnologies has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 85.87 M. Net Loss for the year was (8.31 M) with profit before overhead, payroll, taxes, and interest of 65.58 M.
Latest headline from news.google.com: Is Theratechnologies Inc. stock overhyped or has real potential - Superior risk-adjusted returns - jammulinksnews.com
Theratechnologies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Theratechnologies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Theratechnologies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of February 2024
Upcoming Quarterly Report
View
10th of April 2024
Next Financial Report
View
30th of November 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
31st of August 2023
Last Quarter Report
View
30th of November 2022
Last Financial Announcement
View

Theratechnologies Target Price Consensus

Theratechnologies target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Theratechnologies' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   3  Strong Buy
Most Theratechnologies analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Theratechnologies stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Theratechnologies, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Theratechnologies Target Price Projection

Theratechnologies' current and average target prices are 3.17 and 3.96, respectively. The current price of Theratechnologies is the price at which Theratechnologies is currently trading. On the other hand, Theratechnologies' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Theratechnologies Market Quote on 28th of July 2025

Low Price3.15Odds
High Price3.17Odds

3.17

Target Price

Analyst Consensus On Theratechnologies Target Price

Low Estimate3.6Odds
High Estimate4.4Odds

3.9602

Historical Lowest Forecast  3.6 Target Price  3.96 Highest Forecast  4.4
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Theratechnologies and the information provided on this page.

Know Theratechnologies' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Theratechnologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Theratechnologies backward and forwards among themselves. Theratechnologies' institutional investor refers to the entity that pools money to purchase Theratechnologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Bnp Paribas Arbitrage, Sa2025-03-31
29.8 K
Cyndeo Wealth Partners Llc2025-03-31
29.7 K
Mccormack Advisors International2025-03-31
29.2 K
Acadian Asset Management Llc2025-03-31
28.4 K
Bare Financial Services Inc2025-03-31
26.8 K
Beacon Pointe Advisors, Llc2025-03-31
26.5 K
Advisor Group Holdings, Inc.2025-03-31
26.2 K
Stonepine Capital Management Llc2025-03-31
25.8 K
Geode Capital Management, Llc2025-03-31
25.7 K
Soleus Capital Management, L.p.2025-03-31
4.8 M
Nantahala Capital Management, Llc2025-03-31
2.4 M
Note, although Theratechnologies' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Theratechnologies' market capitalization trends

The company currently falls under 'Small-Cap' category with a current market capitalization of 145.93 M.

Market Cap

51.19 Million

Project Theratechnologies' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.21)(0.22)
Return On Capital Employed 0.45  0.47 
Return On Assets(0.14)(0.15)
Return On Equity 0.38  0.40 
The company has Profit Margin (PM) of (0.11) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.11.
When accessing Theratechnologies' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Theratechnologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Theratechnologies' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Theratechnologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Theratechnologies. Check Theratechnologies' Beneish M Score to see the likelihood of Theratechnologies' management manipulating its earnings.

Evaluate Theratechnologies' management efficiency

Theratechnologies has return on total asset (ROA) of 0.0733 % which means that it generated a profit of $0.0733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.1686) %, meaning that it created substantial loss on money invested by shareholders. Theratechnologies' management efficiency ratios could be used to measure how well Theratechnologies manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Theratechnologies' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 0.40 in 2025, whereas Return On Tangible Assets are likely to drop (0.22) in 2025. At this time, Theratechnologies' Total Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 2.2 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 8 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share(0.59)(0.56)
Tangible Book Value Per Share(0.77)(0.73)
Enterprise Value Over EBITDA 16.65  17.48 
Price Book Value Ratio(2.13)(2.03)
Enterprise Value Multiple 16.65  17.48 
Price Fair Value(2.13)(2.03)
Enterprise Value89.6 M85.1 M
Understanding the operational decisions made by Theratechnologies management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue
2.1289
Revenue
84.4 M
Quarterly Revenue Growth
(0.20)
Revenue Per Share
1.709
Return On Equity
(11.17)
Theratechnologies time-series forecasting models is one of many Theratechnologies' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Theratechnologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Theratechnologies Earnings Estimation Breakdown

The calculation of Theratechnologies' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Theratechnologies is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Theratechnologies is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.23
0.00
Lowest
Expected EPS
0.0
0.00
Highest

Theratechnologies Earnings Projection Consensus

Suppose the current estimates of Theratechnologies' value are higher than the current market price of the Theratechnologies stock. In this case, investors may conclude that Theratechnologies is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Theratechnologies' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 30th of November 2025Current EPS (TTM)
227.55%
-0.2289
0.0
-0.19

Theratechnologies Earnings per Share Projection vs Actual

Actual Earning per Share of Theratechnologies refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Theratechnologies predict the company's earnings will be in the future. The higher the earnings per share of Theratechnologies, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Theratechnologies Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Theratechnologies, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Theratechnologies should always be considered in relation to other companies to make a more educated investment decision.

Theratechnologies Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Theratechnologies' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-07-08
2025-05-31-0.027-0.0904-0.0634234 
2025-04-08
2025-02-280.0430.0023-0.040794 
2025-02-19
2024-11-300.07-0.2289-0.2989427 
2024-10-10
2024-08-310.030.060.03100 
2024-07-10
2024-05-31-0.020.020.04200 
2024-04-10
2024-02-29-0.12-0.10.0216 
2024-02-21
2023-11-30-0.24-0.080.1666 
2023-09-26
2023-08-31-0.29-0.030.2689 
2023-07-12
2023-05-31-0.1-0.11-0.0110 
2023-04-12
2023-02-28-0.38-0.44-0.0615 
2023-02-28
2022-11-30-0.08-0.09-0.0112 
2022-10-13
2022-08-31-0.12-0.080.0433 
2022-07-14
2022-05-31-0.09-0.24-0.15166 
2022-04-13
2022-02-28-0.07-0.09-0.0228 
2022-02-24
2021-11-30-0.07-0.1-0.0342 
2021-10-13
2021-08-31-0.07-0.1-0.0342 
2021-07-15
2021-05-31-0.07-0.070.0
2021-04-14
2021-02-28-0.05-0.07-0.0240 
2021-02-25
2020-11-30-0.06-0.060.0
2020-10-15
2020-08-31-0.06-0.09-0.0350 
2020-07-15
2020-05-31-0.05-0.08-0.0360 
2020-04-14
2020-02-290.01-0.06-0.07700 
2020-02-25
2019-11-30-0.01-0.08-0.07700 
2019-10-08
2019-08-31-0.01-0.02-0.01100 
2019-07-11
2019-05-310.01-0.04-0.05500 
2019-04-04
2019-02-280.01-0.02-0.03300 
2019-02-21
2018-11-300.0038-0.0152-0.019500 
2018-10-04
2018-08-31-0.010.00360.0136136 
2018-07-05
2018-05-31-0.02-0.020.0
2018-04-05
2018-02-28-0.03-0.030.0
2018-02-07
2017-11-30-0.02-0.03-0.0150 
2017-10-05
2017-08-31-0.02-0.03-0.0150 
2017-07-12
2017-05-31-0.02-0.1-0.08400 
2017-04-06
2017-02-280.01-0.03-0.04400 
2017-02-08
2016-11-300.010.010.0
2016-10-04
2016-08-310.020.01-0.0150 
2016-07-05
2016-05-310.02-0.01-0.03150 
2016-03-31
2016-02-290.02-0.0017-0.0217108 
2016-02-24
2015-11-300.020.01-0.0150 
2015-10-01
2015-08-310.020.020.0
2015-07-14
2015-05-31-0.020.010.03150 
2015-04-14
2015-02-28-0.03-0.010.0266 
2015-02-26
2014-11-30-0.09-0.060.0333 
2014-02-27
2013-11-30-0.02-0.04-0.02100 
2013-10-10
2013-08-31-0.01-0.03-0.02200 
2013-07-10
2013-05-31-0.01-0.02-0.01100 
2013-02-27
2012-11-30-0.04-0.07-0.0375 
2012-10-11
2012-08-31-0.01-0.010.0
2012-07-12
2012-05-31-0.03-0.020.0133 
2012-04-13
2012-02-29-0.08-0.020.0675 
2012-02-08
2011-11-30-0.07-0.020.0571 
2011-10-13
2011-08-31-0.07-0.060.0114 
2011-07-07
2011-05-31-0.08-0.1-0.0225 
2011-04-12
2011-02-28-0.05-0.1-0.05100 
2011-02-09
2010-11-300.330.350.02
2010-10-12
2010-08-310.03-0.05-0.08266 
2010-07-07
2010-05-31-0.07-0.08-0.0114 
2010-03-23
2010-02-28-0.08-0.070.0112 
2010-02-10
2009-11-30-0.08-0.080.0
2009-10-05
2009-08-31-0.070.10.17242 
2009-07-07
2009-05-31-0.12-0.090.0325 
2009-03-25
2009-02-28-0.12-0.18-0.0650 
2009-02-09
2008-11-300.07-0.27-0.34485 
2008-10-09
2008-08-31-0.17-0.19-0.0211 
2008-07-09
2008-05-31-0.17-0.2-0.0317 
2008-03-25
2008-02-29-0.18-0.2-0.0211 
2008-01-23
2007-11-30-0.18-0.19-0.01
2007-10-10
2007-08-31-0.14-0.18-0.0428 
2007-07-10
2007-05-31-0.15-0.150.0
2007-03-28
2007-02-28-0.12-0.2-0.0866 
2007-02-08
2006-11-30-0.14-0.15-0.01
2006-10-12
2006-08-31-0.12-0.16-0.0433 
2006-07-05
2006-05-31-0.12-0.14-0.0216 
2006-03-29
2006-02-28-0.18-0.150.0316 
2006-02-08
2005-11-30-0.2-0.160.0420 
2005-10-13
2005-08-31-0.17-0.150.0211 
2005-07-13
2005-05-31-0.17-0.36-0.19111 
2005-04-13
2005-02-280.270.26-0.01
2005-02-03
2004-11-30-0.14-0.31-0.17121 
2004-10-13
2004-08-31-0.16-0.120.0425 
2004-07-13
2004-05-31-0.19-0.170.0210 
2004-04-19
2004-02-29-0.24-0.20.0416 
2004-01-15
2003-11-30-0.21-0.45-0.24114 
2003-10-15
2003-08-31-0.2-0.21-0.01
2003-07-14
2003-05-31-0.21-0.22-0.01
2003-04-15
2003-02-28-0.22-0.180.0418 
2003-01-15
2002-11-30-0.19-0.25-0.0631 
2002-10-15
2002-08-31-0.25-0.190.0624 
null
nullnullnullnull
2002-04-15
2002-02-28-0.08-0.11-0.0337 
2002-02-15
2001-11-30-0.3-0.20.133 
2001-10-15
2001-08-31-0.18-0.150.0316 
2001-04-15
2001-02-28-0.06-0.09-0.0350 
2000-10-15
2000-08-31-0.10.20.3300 

Theratechnologies Corporate Management

LLB BAVP AffairsProfile
H MScVice ResourcesProfile
LLB LLMGeneral SecretaryProfile
Elif McDonaldDirector RelationsProfile
Joanne ChoiSenior RelationsProfile

Additional Tools for Theratechnologies Stock Analysis

When running Theratechnologies' price analysis, check to measure Theratechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theratechnologies is operating at the current time. Most of Theratechnologies' value examination focuses on studying past and present price action to predict the probability of Theratechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theratechnologies' price. Additionally, you may evaluate how the addition of Theratechnologies to your portfolios can decrease your overall portfolio volatility.